The Endpoints 11: The top private biotechs in pursuit of new drugs. Pushing the envelope with powerful new technologies

Right around the beginning of the year, we got a close-up look at what happens after a boom ripples through biotech. The crash of life sciences stocks in Q1 was heard around the world.

In the months since, we’ve seen the natural Darwinian down cycle take effect. Reverse mergers made...

Click to view original post